RE:The earlier that I/O therapy is administered ... the betterThe earlier the better is what ONCY is seeing with the use of pelareorep in combination with PD-(L)1 immune checkpoint inhibitors in the treatment of multile cancers. ONCY is demonstrating this concept in its Phase 2 Goblet trial with cohort 1 in 1st line pancreatic cancer, in which the most recent results have been a complete result and stable disease outcome in the majority of the rest.